Table 5.

Summary of adverse events

VariablesValganciclovir (n=60)Valacyclovir (n=59)P Value
Leukopenia20 (33)13 (22)0.24
Neutropenia21 (35)13 (22)0.17
G-CSF treatment10 (17)3 (5)0.08
Thrombocytopenia9 (15)11 (19)0.76
Anemia8 (13)11 (19)0.56
Hallucinations/confusion9 (15)13 (22)0.45
 Moderate to severe7 (12)6 (10)0.97
Headache6 (10)2 (3)0.29
Insomnia3 (5)2 (3)0.99
Nausea15 (25)14 (24)0.96
Diarrhea22 (37)26 (44)0.53
New-onset diabetes or IGTa23 (41)18 (35)0.62
Hypercholesterolemia45 (75)50 (85)0.27
Elevated liver enzymes15 (25)25 (42)0.07
Cardiovascular events14 (23)11 (19)0.69
Malignancy1 (2)0 (0)0.99
Study drug discontinuationb13 (22)6 (10)0.14
  • Data are n (%) unless otherwise indicated. G-CSF, granulocyte colony–stimulating factor; IGT, impaired glucose tolerance.

  • a Patients without diabetes before transplantation were analyzed.

  • b Reasons for discontinuation in valganciclovir prophylaxis were leukopenia and neutropenia (13), and reasons for discontinuation in valacyclovir prophylaxis were leukopenia and neutropenia (3), hallucinations/confusion (1), and oral drugs intolerance (1).